The effect of lithium in post-stroke motor recovery: A double-blind, placebo-controlled, randomized clinical trial

Clinical Neuropharmacology

Volumn 37, Issue 3, 2014, Pages 73-78

  Mohammadianinejad, Seyed Ehsan ^a   Majdinasab, Nastaran ^a   Sajedi, Seyed Aidin ^a   Abdollahi, Fahimeh ^a   Moqaddam, Mehdi Masoudi ^a   Sadr, Fatemeh ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

clinical trial; functional recovery; ischemic stroke; lithium; motor rehabilitation; neuroprotection; treatment

Indexed keywords

LITHIUM; PLACEBO; LITHIUM CARBONATE; NEUROPROTECTIVE AGENT;

ADULT; ARM MOVEMENT; ARTICLE; BRAIN REGION; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HAND SUBSECTION OF FUGL MEYER ASSESSMENT; HUMAN; LITHIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY; MOTOR ACTIVITY; MOTOR PERFORMANCE; MOTOR RECOVERY; MUSCLE DISEASE; MUSCLE TWITCH; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; XEROSTOMIA; AGED; BRAIN; BRAIN CORTEX; BRAIN ISCHEMIA; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NERVE CELL; PATHOPHYSIOLOGY; PILOT STUDY; PSYCHOMOTOR PERFORMANCE; STROKE; VASCULARIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN; BRAIN ISCHEMIA; CEREBRAL CORTEX; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LITHIUM CARBONATE; LOST TO FOLLOW-UP; MALE; MIDDLE AGED; MOTOR SKILLS; NEURONS; NEUROPROTECTIVE AGENTS; PILOT PROJECTS; PSYCHOMOTOR PERFORMANCE; STROKE;

EID: 84901366956     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000028     Document Type: Article

References (32)

1. Gold AB, Herrmann N, Lanctot KL. Lithium and its neuroprotective and neurotrophic effects: Potential treatment for post-ischemic stroke sequelae. Curr Drug Targets 2011;12(2):243-255
2. Hashimoto R, Hough C, Nakazawa T, et al. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: Involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002;80(4):589-597. (Pubitemid 34809967
3. Hashimoto R, Takei N, Shimazu K, et al. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: An essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 2002;43(7):1173-1179. (Pubitemid 36009371
4. Chalecka-Franaszek E, Chuang D-M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 1999;96(15):8745-8750. (Pubitemid 29354862
5. Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord 2002;4(2):137-144. (Pubitemid 34411276
6. Chen R-W, Chuang D-M. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999; 274(10):6039-6042. (Pubitemid 29111005
7. Manji HK, Moore GJ, Chen G. Lithium at 50: Have the neuroprotective effects of this unique cation been overlooked?. Biol Psychiatry 1999;46(7):929-940
8. Jefferson J, Greist J. Lithium. In: Sadock B, Sadock V, Ruiz P, eds. Comprehensive Textbook of Psychiatry. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:3132-3145
9. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 1993;24(1):35-41
10. Lyden PD, Lu M, Levine SR, et al. A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: Preliminary reliability and validity. Stroke 2001;32(6):1310-1317
11. Gladstone DJ, Danells CJ, Black SE. The fugl-meyer assessment of motor recovery after stroke: A critical review of its measurement properties. Neurorehabil Neural Repair 2002;16(3): 232-240. (Pubitemid 34984898
12. Duncan PW, Goldstein LB, Matchar D, et al. Measurement of motor recovery after stroke. Outcome assessment and sample size requirements. Stroke 1992;23(8):1084-1089
13. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Erlbaum; 1988
14. Krakauer JW. Arm function after stroke: From physiology to recovery. Semin Neurol 2005;25(4):384-395
15. Choi D. Antagonizing excitotoxicity: A therapeutic strategy for stroke?. Mt Sinai J Med 1998;65(2):133-138
16. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986;19(2):105-111. (Pubitemid 16114163
17. Davalos A, Castillo J, Serena J, et al. Duration of glutamate release after acute ischemic stroke. Stroke 1997;28(4):708-710. (Pubitemid 27161450
18. Broughton BR, Reutens DC, Sobey CG. Apoptotic mechanisms after cerebral ischemia. Stroke 2009;40(5):e331-e339
19. Kokaia Z, Zhao Q, Kokaia M, et al. Regulation of brain-derived neurotrophic factor gene expression after transient middle cerebral artery occlusion with and without brain damage. Exp Neurol 1995; 136(1):73-88
20. Lee TH, Yang JT, Kato H, et al. Expression of brain-derived neurotrophic factor immunoreactivity and mRNA in the hippocampal CA1 and cortical areas after chronic ischemia in rats. J Neurosci Res 2004;76(5):705-712. (Pubitemid 38691793
21. Sato Y, Chin Y, Kato T, et al. White matter activated glial cells produce BDNF in a stroke model of monkeys. Neurosci Res 2009;65(1):71-78
22. Ploughman M, Windle V, MacLellan CL, et al. Brain-derived neurotrophic factor contributes to recovery of skilled reaching after focal ischemia in rats. Stroke 2009;40(4):1490-1495
23. MacDonald E,Van der Lee H, Pocock D, et al. A novel phosphodiesterase type 4 inhibitor, HT-0712, enhances rehabilitation-dependent motor recovery and cortical reorganization after focal cortical ischemia. Neurorehabil Neural Repair 2007;21(6):486-496. (Pubitemid 47585201
24. Kleim JA, Chan S, Pringle E, et al. BDNF val66met polymorphism is associated with modified experience-dependent plasticity in human motor cortex. Nat Neurosci 2006;9(6):735-737
25. Moore GJ, Bebchuk JM, Hasanat K, et al. Lithium increases N-Acetyl-Aspartate in the human brain: In vivo evidence in support of bcl-2's neurotrophic effects?. Biol Psychiatry 2000;48(1):1-8
26. Moore GJ, Bebchuk JM, Wilds IB, et al. Lithium-induced increase in human brain grey matter. Lancet 2000;356(9237):1241-1242
27. Moore GJ, Cortese BM, Glitz DA, et al. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry 2009;70(5):699-705
28. Monkul ES, Matsuo K, Nicoletti MA, et al. Prefrontal gray matter increases in healthy individuals after lithium treatment: A voxel-based morphometry study. Neurosci Lett 2007;429(1):7-11. (Pubitemid 350116344
29. Feys H, Hetebrij J, Wilms G, et al. Predicting arm recovery following stroke: Value of site of lesion. Acta Neurol Scand 2000;102(6):371-377
30. Shelton FN, Reding MJ. Effect of lesion location on upper limb motor recovery after stroke. Stroke 2001;32(1):107-112. (Pubitemid 32063832
31. Nakayama H, Jorgensen HS, Raaschou HO, et al. Recovery of upper extremity function in stroke patients: The Copenhagen Stroke Study. Arch Phys Med Rehabil 1994;75(4):394-398. (Pubitemid 24134114
32. Gresham GE, Fitzpatrick TE, Wolf PA, et al. Residual disability in survivors of stroke - The Framingham study. N Engl J Med 1975; 293(19):954-956